Pharmaceutical & Diagnostic Innovation

, Volume 3, Issue 6, pp 10–13 | Cite as

ASCO Spotlight Falls on Targeted Therapies

Emerging Technology

As in previous years, targeted cancer therapies dominated the 2005 American Society of Clinical Oncology (ASCO) annual meeting. The appeal of targeted cancer therapies is the potential for improved efficacy and fewer adverse effects. Traditional chemotherapy agents are nonselective, targeting all rapidly dividing cells including those in the blood, gastrointestinal tract and mouth. These treatments have moderate efficacy and typically produce only palliative effects in patients with advanced disease. In contrast, targeted therapies block the growth and spread of tumors by interfering with specific molecules involved in carcinogenesis.

When it comes to targeted cancer therapeutics, many are familiar with Avastin™, Gleevec®, Herceptin®, Iressa® and Tarceva®.1 Set to join them in the spotlight are four late-stage targeted therapies: sorafenib from Bayer and Onyx Pharmaceuticals; sunitinib from Pfizer; lapatinib from GlaxoSmithKline (GSK); and vatalanib from Novartis and Schering AG.



Sorafenib Metastatic Breast Cancer Sunitinib Lapatinib Herceptin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Bayer, Onyx Pharmaceuticals. Sorafenib (BAY 43-9006) doubles progression-free survival in phase III kidney cancer trial. Media release: 14 May 2005Google Scholar
  2. 2.
    Onyx Pharmaceuticals. Bayer and Onyx unblind patients in ongoing sorafenib phase III clinical trial in advanced renal cell carcinoma. Media release: 18 Apr 2005Google Scholar
  3. 3.
    European Pharmaceuticals. Bayer: Feedback from LB pre-ASCO dinner with sorafenib primary investigator. New York: Lehman Brothers Equity Research, 2005Google Scholar
  4. 4.
    European Pharmaceuticals. Major Pharmaceuticals: ASCO update — day 1 and 2 review. New York: Lehman Brothers Equity Research, 2005Google Scholar
  5. 5.
    Pfizer. New data show Pfizer’s SUTENT/SU11248 (sunitinib malate) extends overall survival in Gleevec-resistant GIST. Media release: 17 May 2005Google Scholar
  6. 6.
    Novartis. First results from PTK/ZK CONFIRM 1 trial presented at American Society of Clinical Oncology show positive drug effects in advanced colorectal cancer. Media release: 13 May 2005Google Scholar
  7. 7.
    Novartis PTK/ZK 787 data presented at ASCO; survival analysis pending. Pink Sheet 2005; 67 (22): 20Google Scholar
  8. 8.
    GlaxoSmithKline. GlaxoSmithKline issues update on lapatinib: new clinical data and regulatory filing plans. Media release: 15 May 2005Google Scholar
  9. 9.
    GSK lapatinib breast cancer development shifts to front-line setting. Pink Sheet 2005; 67 (21): 13Google Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations